diabetes glp-1 agonist Trends in the Development of Receptor Agonists Targeting GLP-1, GIP & GCG

Description

Check our guide on retatrutide availability for the latest status updates

Notably, nearly 50% of the retatrutide phase 2 obesity trial were men, which is higher than in phase 3 clinical trials with tirzepatide (32.5% in SURMOUNT-1 [27]) and semaglutide 2.4 mg (25.9% in STEP-1 [8])

Not all will qualify

Through increased labeling of BCKA-derived metabolites and increases in levels of BCAA breakdown, such as glutamate, alanine, and 3-hydroxyisobutyric acid, they discovered that tirzepatide treatment stimulated catabolism of BCAAs/BCKAs in BAT

But it takes thoughtful consideration of how or if you will offer coverage, what tools youll have in place to help ensure your drug spend aligns with your coverage strategy, and effective ways you can empower your members to learn and put in practice the necessary lifestyle changes that are critical to achieving and sustaining better outcomes